Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis

Animesh D Pardanani, J. Gotlib, A. W. Roberts, M. Wadleigh, S. Sirhan, J. Kawashima, J. A. Maltzman, L. Shao, V. Gupta, Ayalew Tefferi

Research output: Contribution to journalLetter

7 Scopus citations
Original languageEnglish (US)
Pages (from-to)1034-1037
Number of pages4
JournalLeukemia
Volume32
Issue number4
DOIs
StatePublished - Apr 1 2018

ASJC Scopus subject areas

  • Hematology
  • Cancer Research
  • Anesthesiology and Pain Medicine

Cite this

Pardanani, A. D., Gotlib, J., Roberts, A. W., Wadleigh, M., Sirhan, S., Kawashima, J., Maltzman, J. A., Shao, L., Gupta, V., & Tefferi, A. (2018). Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis. Leukemia, 32(4), 1034-1037. https://doi.org/10.1038/leu.2017.330